Kyntra Bio, Inc. (KYNB) stock
KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.04−1.16 (-36.25%)
Close on Nov 17, 2026Market cap $8.26MP/E 0.0Yield –
Kyntra Bio cash
Cash and short-term investments held at the end of each period.
Kyntra Bio's cash was $91.32M at Jun 30, 2026. For fiscal 2025 it was $88.98M, up 76.3% from the year before. Over ten years it grew -6.9% a year on average. The highest annual figure on record is $735.72M in fiscal 2017.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.98M | +76.3% |
| FY2024 | Dec 31, 2024 | $50.48M | -75.2% |
| FY2023 | Dec 31, 2023 | $203.45M | -51.8% |
| FY2022 | Dec 31, 2022 | $422.01M | +4.2% |
| FY2021 | Dec 31, 2021 | $405.19M | -41.0% |
| FY2020 | Dec 31, 2020 | $686.54M | +28.6% |
| FY2019 | Dec 31, 2019 | $533.76M | -14.1% |
| FY2018 | Dec 31, 2018 | $621.40M | -15.5% |
| FY2017 | Dec 31, 2017 | $735.72M | +190.6% |
| FY2016 | Dec 31, 2016 | $253.18M | +39.7% |
| FY2015 | Dec 31, 2015 | $181.17M | +0.8% |
| FY2014 | Dec 31, 2014 | $179.82M | +135.6% |
| FY2013 | Dec 31, 2013 | $76.33M | +96.4% |
| FY2012 | Dec 31, 2012 | $38.87M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $91.32M | +290.8% |
| Q1 FY2026 | Mar 31, 2026 | $87.24M | +159.6% |
| Q4 FY2025 | Dec 31, 2025 | $88.98M | +76.3% |
| Q3 FY2025 | Sep 30, 2025 | $117.98M | -9.9% |
| Q2 FY2025 | Jun 30, 2025 | $23.37M | -83.4% |
| Q1 FY2025 | Mar 31, 2025 | $33.61M | -81.1% |
| Q4 FY2024 | Dec 31, 2024 | $50.48M | -75.2% |
| Q3 FY2024 | Sep 30, 2024 | $131.00M | -47.9% |
| Q2 FY2024 | Jun 30, 2024 | $140.71M | -58.1% |
| Q1 FY2024 | Mar 31, 2024 | $177.60M | -50.1% |
| Q4 FY2023 | Dec 31, 2023 | $203.45M | -51.8% |
| Q3 FY2023 | Sep 30, 2023 | $251.34M | -38.5% |
| Q2 FY2023 | Jun 30, 2023 | $335.72M | -23.4% |
| Q1 FY2023 | Mar 31, 2023 | $355.95M | -16.8% |
| Q4 FY2022 | Dec 31, 2022 | $422.01M | +4.2% |
| Q3 FY2022 | Sep 30, 2022 | $408.52M | -16.0% |
| Q2 FY2022 | Jun 30, 2022 | $438.13M | -13.6% |
| Q1 FY2022 | Mar 31, 2022 | $428.08M | -21.3% |
| Q4 FY2021 | Dec 31, 2021 | $405.19M | -41.0% |
| Q3 FY2021 | Sep 30, 2021 | $486.40M | -29.3% |
| Q2 FY2021 | Jun 30, 2021 | $507.21M | -26.0% |
| Q1 FY2021 | Mar 31, 2021 | $544.23M | +1.6% |
| Q4 FY2020 | Dec 31, 2020 | $686.54M | +28.6% |
| Q3 FY2020 | Sep 30, 2020 | $687.87M | +9.4% |
| Q2 FY2020 | Jun 30, 2020 | $685.59M | +3.8% |
| Q1 FY2020 | Mar 31, 2020 | $535.43M | -5.3% |
| Q4 FY2019 | Dec 31, 2019 | $533.76M | -14.1% |
| Q3 FY2019 | Sep 30, 2019 | $628.63M | -3.7% |
| Q2 FY2019 | Jun 30, 2019 | $660.76M | -1.7% |
| Q1 FY2019 | Mar 31, 2019 | $565.40M | -19.7% |
| Q4 FY2018 | Dec 31, 2018 | $621.40M | -15.5% |
| Q3 FY2018 | Sep 30, 2018 | $652.73M | -10.6% |
| Q2 FY2018 | Jun 30, 2018 | $671.90M | +87.0% |
| Q1 FY2018 | Mar 31, 2018 | $703.77M | +189.1% |
| Q4 FY2017 | Dec 31, 2017 | $735.72M | +190.6% |
| Q3 FY2017 | Sep 30, 2017 | $729.97M | +201.9% |
| Q2 FY2017 | Jun 30, 2017 | $359.40M | – |
| Q1 FY2017 | Mar 31, 2017 | $243.42M | – |
| Q4 FY2016 | Dec 31, 2016 | $253.18M | – |
| Q3 FY2016 | Sep 30, 2016 | $241.81M | – |
See a number that looks wrong?